KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBIT Margin: 2010-2025

Historic EBIT Margin for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to -109.95%.

  • TherapeuticsMD's EBIT Margin rose 9736.00% to -109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was -61.80%, marking a year-over-year increase of 35649.00%. This contributed to the annual value of -270.30% for FY2024, which is 38431.00% up from last year.
  • Latest data reveals that TherapeuticsMD reported EBIT Margin of -109.95% as of Q3 2025, which was down 50.61% from -73.00% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBIT Margin registered a high of 104.95% during Q4 2024, and its lowest value of -4,269.25% during Q2 2022.
  • For the 3-year period, TherapeuticsMD's EBIT Margin averaged around -630.61%, with its median value being -320.92% (2023).
  • As far as peak fluctuations go, TherapeuticsMD's EBIT Margin crashed by 411,631bps in 2022, and later skyrocketed by 370,358bps in 2023.
  • Quarterly analysis of 5 years shows TherapeuticsMD's EBIT Margin stood at -189.48% in 2021, then surged by 26,014bps to 70.65% in 2022, then slumped by 39,157bps to -320.92% in 2023, then spiked by 42,586bps to 104.95% in 2024, then soared by 9,736bps to -109.95% in 2025.
  • Its last three reported values are -109.95% in Q3 2025, -73.00% for Q2 2025, and -221.63% during Q1 2025.